Journal
DIABETES RESEARCH AND CLINICAL PRACTICE
Volume 191, Issue -, Pages -Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.diabres.2022.110038
Keywords
Fatty liver; Pregnancy; Maternal outcome; Neonatal outcomes; Gestational diabetes mellitus
Categories
Funding
- Western Sydney Local Health District Research Education Network Grant 2021 by the Western Sydney Local Health District Research Education Network, Westmead Hospital, Australia
- Institute of Clinical Pathology & Medical Research (ICPMR), Westmead Hospital, Australia
- Robert W. Storr Bequest to the Sydney Medical Foundation, The University of Sydney, Australia
- National Health and Medical Research Council of Australia, Australia (NHMRC) [APP1053206, APP1149976, APP1107178, APP1108422]
- Diabetes Australia Research Program 2021, Australia [Y21GCHEW]
Ask authors/readers for more resources
This study aimed to determine the prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) and its impact on adverse pregnancy outcomes in women with gestational diabetes mellitus (GDM). The results showed that almost 40% of women in the GDM cohort had MAFLD detected in mid-to-late gestation. However, MAFLD was not associated with worse pregnancy outcomes.
Aims: To determine the prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) and its as-sociation on adverse pregnancy outcomes in women with gestational diabetes mellitus (GDM).Methods: 380 women with GDM had a FibroScan (R) performed between 24 and 32 weeks. A Controlled Attenuation Parameter (CAP) >= 233.5 dB/m signified MAFLD. Gestational hypertension, pre-eclampsia and eclampsia contributed to a composite of adverse maternal outcomes. A composite of adverse neonatal outcomes included pre-term birth, hypoglycaemia, small/large-for-gestational age and admission to neonatal high dependency. Multiple logistic regression was used to determine independent associations with MAFLD.Results: 147 (38.7 %) women had MAFLD. Higher pre-pregnancy BMI (median 28.4, IQR 24.7-33.0 kg/m(2) vs median 24.0, IQR 21.7-26.5 kg/m(2), p < 0.01) and rates of insulin therapy (62.2 % vs 40.7 %, p < 0.01) occurred in MAFLD over non-MAFLD women. MAFLD was independently associated with obesity (aOR 4.73 [95 % CI 2.53-8.86]) and insulin therapy (aOR 1.79 [95 % CI 1.12-2.85]). MAFLD and non-MAFLD women had com-parable rates of adverse maternal (7.7 % vs 9.5 %, p = 0.56) and neonatal outcomes (75.4 % vs 68.8 %, p = 0.18). Conclusions: Within this GDM cohort, almost 40% had FibroScan (R)-detected MAFLD in mid-to-late gestation. MAFLD was not associated with worse pregnancy outcomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available